The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
…, P Yañez, N Li, S Lonardi, O Kolesnik, O Barajas, Y Bai… - Nature, 2021 - nature.com
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 …
Z Ren, J Xu, Y Bai, A Xu, S Cang, C Du, Q Li… - The Lancet …, 2021 - thelancet.com
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV)
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …
Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous …
H Luo, J Lu, Y Bai, T Mao, J Wang, Q Fan, Y Zhang… - Jama, 2021 - jamanetwork.com
Importance Standard first-line therapy for advanced or metastatic esophageal carcinoma is
chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death …
chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death …
[PDF][PDF] Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the …
J Li, S Qin, J Xu, J Xiong, C Wu, Y Bai, W Liu… - Journal of Clinical …, 2016 - mrimedical.net
Purpose There is currently no standard treatment strategy for patients with advanced metastatic
gastric cancer experiencing progression after two or more lines of chemotherapy. We …
gastric cancer experiencing progression after two or more lines of chemotherapy. We …
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer …
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a …
Background In the international randomised phase 3 CORRECT trial (NCT01103323),
regorafenib significantly improved overall survival versus placebo in patients with treatment-…
regorafenib significantly improved overall survival versus placebo in patients with treatment-…
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a …
…, E Li, H Lu, Y Pan, J Xiong, Y Yuan, Y Bai… - The Lancet …, 2020 - thelancet.com
Background Patients with advanced or metastatic oesophageal squamous cell carcinoma
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …
[PDF][PDF] Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced …
S Qin, Y Bai, HY Lim, S Thongprasert, Y Chao, J Fan… - J Clin …, 2013 - researchgate.net
… Yuxian Bai, Third Affiliated Hospital, Harbin Medical University, Harbin; Jia Fan, Zhong- …
Provision of study materials or patients: Shukui Qin, Yuxian Bai, Sumitra Thongprasert, Tsai-Shen …
Provision of study materials or patients: Shukui Qin, Yuxian Bai, Sumitra Thongprasert, Tsai-Shen …
[PDF][PDF] Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial
J Li, S Qin, J Xu, W Guo, J Xiong, Y Bai, G Sun… - J clin …, 2013 - scholar.archive.org
Purpose Patients with metastatic gastric cancer (mGC) who do not respond to or who
experience progression with second-line chemotherapy have no treatment options that clearly …
experience progression with second-line chemotherapy have no treatment options that clearly …
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro …
…, Y He, Z Zhang, Y Sun, Y Li, H Chen, Y Bai… - The Lancet …, 2021 - thelancet.com
Background The optimal perioperative chemotherapeutic regimen for locally advanced
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …